Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2831781 Phase I in Healthy Volunteers
NCT03965533Phase 1Completed
- Sponsor
- GSK
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IMP731 in ulcerative colitis (UC) and psoriasis (7 arms), sponsored by GSK. Primary endpoints: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs), Number of Participants With Vital Signs of Potential Clinical Importance and 3 more. Started Jun 2019; status: completed.
02
Drugs
IMP731
03
Conditions
ulcerative colitis (UC)psoriasis
Beyond the preview
Go deeper on NCT03965533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965533.